Skip to main content
Fig. 1 | Neurological Research and Practice

Fig. 1

From: INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas

Fig. 1

Intercept H3 treatment schedule

H3K27M-vac will be administered to 15 patients with newly diagnosed H3K27M mutant DMG concomitant to standard radiotherapy and subsequently in combination with ATE. Longitudinal blood and CSF sampling will allow immunogenicity testing and three-monthly MRIs together with regular clinical evaluation will be used to determine clinical response

Back to article page

Neurological Research and Practice

ISSN: 2524-3489

Contact us